ALPN News and Press, Alpine Immune Sciences Inc. From 01/24/20

Thinly traded nano cap Alpine Immune Sciences (NASDAQ: ALPN ) is up  8%  premarket, albeit on only 1,008 shares, on the heels of new preclinical data on lead candidate ALPN-101. The results were presented at the Crohn's & Colitis Congress in Austin, TX. More news on: Alpine...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead autoimmune/inflammatory clinical program, ALPN-101, at the 2020 Cr...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s & Colitis Congress taking pl...

ALPN-101 demonstrates ability to potently inhibit both T and B cell responses in first-in-human study Human experience supports both IV and SQ dosing regimens Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovativ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at the 31 st Annual Piper Jaffray Heal...

Alpine Immune Sciences, Inc. (ALPN) Q3 2019 Earnings Conference Call November 13, 2019 4:30 PM ET Company Participants Courtney Dugan - Investor Relations Mitchell Gold - Chairman & Chief Executive Officer Stanford Peng - President & Head, Research & Development Pau...

Alpine Immune Sciences (NASDAQ: ALPN ): Q3 GAAP EPS of -$0.62 beats by $0.06 . Revenue of $0.29M beats by $0.1M . Press Release More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30 p.m. ET Today Alpine Immune Sciences, Inc. (NASDAQ:ALP...